Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 16, 2007

Cytonet and Vesta Therapeutics Collaborate on Liver Cell Therapy

  • Cytonet and Vesta Therapeutics signed a mutual strategic collaboration agreement that involves the construction of a GMP facility, in accordance with European standards, on the premises of Vesta Therapeutics in Durham, NC. Liver cell products for Cytonet’s clinical trials will be produced at the facility in the future.

    Cytonet says it has managed to refine techniques of cell isolation and processing to the extent that human liver cells can be obtained in medicinal product quality in a routine production process. The goal is to treat various liver disease.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »